At a glance
ClinicalIndex Comparison RecordPhase 2Unknown· 40 target
Drug / intervention
Zanubrutinib +1 moredrug
Likely dose
Zanubrutinib 160mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study on the Safety and Efficacy of Zanubrutinib Combined With Tislelizumab in the Treatment of Relapsed/Refractory Primary Mediastinal Large B-cell Lymphoma and Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma
In Brief
A Phase 2 clinical trial evaluating Zanubrutinib and Tislelizumab for Primary Mediastinal Large B Cell Lymphoma and EBV-Positive DLBCL, Nos. Targeting 40 participants across 1 site.
Detailed Summary
The study is to investigate the safety and efficacy of Zanubrutinib combined with Tislelizumab in the treatment of relapsed/refractory primary mediastinal large B-cell lymphoma and Epstein-Barr Virus-positive diffuse large B-cell lymphoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--
Timeline
Phase 2UnknownOverdue
202120222023202420252026
Enrollment StartJan 2021
First PostedJan 2021
Primary CompletionJan 2023
Study CompletionJan 2024
TodayJul 2026
First PostedJan 12, 2021
Enrollment StartJan 1, 2021
Primary CompletionJan 1, 2023
Study CompletionJan 1, 2024
TodayJul 1, 2026
Enrollment to primary: 2 yearsPosted 5.5 years ago
Interventions
Zanubrutinibdrug
160mg Bid, D1-21, po
Tislelizumabdrug
200mg, D1, ivgtt